FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
Hosted on MSN14d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
They receive esketamine at a certified doctor’s office or in a clinic, where a health care provider watches over them for at least two hours after the dose. (When the FDA first approved ...
The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...
The FDA previously required combination use with traditional antidepressants. According to J&J, the treatment demonstrated superior improvement in depressive symptoms compared to placebo as quickly as ...
“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback